Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)Business Wire • 05/04/26
PID: This Dividend ETF May Expose Itself To Geopolitical And Sector-Specific RiskSeeking Alpha • 02/19/25